CTOs on the Move

HealthEd

www.HealthEd.com

 
HealthEd is a specialized agency that uses education to help people develop the knowledge, skills, motivation, and confidence to manage important health decisions and activities and ultimately achieve better health outcomes.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.HealthEd.com
  • 100 Walnut Ave Ste 407
    Clark, NJ USA '07066
  • Phone: 908.389.2129

Executives

Name Title Contact Details

Similar Companies

Perot Systems Corporation

Perot Systems Corporation is a Plano, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Massive Bio

Increasing Accessibility to Clinical Trials and Personalized Cancer Treatment Options. Every cancer patient is different and deserves treatment of the highest quality that is personalized, affordable, and easily accessible. Massive Bio translates the world-class oncology knowledge of the large cancer centers​ experts, facilitates a virtual tumor board collaboratively with the treating oncologist, and advises the patient and treating oncologist to operationalize these expert recommendations at the point of care thereby, eliminating additional time, travel, and cost. 85% of US cancer patients receive treatments in community practices where treating oncologists are overwhelmed with the influx of new tests and treatments while trying to manage their busy practices. We believe all cancer patients deserve equal access to the latest in cancer research and treatment.

Gauthier Biomedical

Gauthier Biomedical is a Grafton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Upper Missouri District Health Unit

The Upper Missouri District Health Unit is a Williston, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.